Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS

Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS

• Data reinforce importance of early initiation and continuation of OCREVUS treatment
• New analyses highlight the need for active treatment in underrepresented populations, such as primary progressive MS (PPMS) patients with more advanced disability and relapsing MS (RMS) patients of African-descent
• Genentech continues to advance the clinical understanding of MS with new studies incorporating novel clinical endpoints and digital tools